Abstract
The prevalence of etravirine resistance mutations was examined in genotypes derived from 1343 HIV-infected patients failing nevirapine or efavirenz in the resistance database of the Spanish AIDS Research Network (ResRIS). Overall, etravirine-resistant genotypes were recognized in 18.7% of patients, with no significant differences between failures under nevirapine or efavirenz. Thus, more than 80% patients with prior failure to nonnucleoside reverse transcriptase inhibitors could potentially benefit from etravirine rescue therapy.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Alkynes
-
Anti-HIV Agents / therapeutic use
-
Benzoxazines / therapeutic use
-
Cyclopropanes
-
Drug Resistance, Viral / genetics*
-
HIV-1 / genetics*
-
Humans
-
Mutation / genetics*
-
Nevirapine / therapeutic use
-
Nitriles
-
Pyridazines / therapeutic use*
-
Pyrimidines
-
Reverse Transcriptase Inhibitors / therapeutic use*
-
Spain
-
Treatment Failure
Substances
-
Alkynes
-
Anti-HIV Agents
-
Benzoxazines
-
Cyclopropanes
-
Nitriles
-
Pyridazines
-
Pyrimidines
-
Reverse Transcriptase Inhibitors
-
etravirine
-
Nevirapine
-
efavirenz